Semaglutide (Wegovy) Treatment for Trichotillomania

Sponsor
University of Chicago
Study ID
NCT07282769
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Hair Pulling
  • Hair Pulling Disorder
  • Hair-Pulling Disorder
  • Trichotillomania
  • Trichotillomania (Hair-Pulling Disorder)

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    All participants in the study will receive semaglutide (Wegovy).

Study Details

This research study is testing the effectiveness and safety of semaglutide (Wegovy) in people with trichotillomania, also known as hair-pulling disorder.

Key Dates

Start date
Jun 30, 2026
Status verified
Jun 2026
Primary completion
Feb 28, 2027
Completion
Feb 28, 2027

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide (Wegovy)
    Participants will receive semaglutide (Wegovy) weekly for 8 weeks.

Primary Outcome Measure

NIMH Trichotillomania Severity Scale [ Time Frame: From screening to 1 week after last dose of study drug ]

Central Contacts

Related Studies